• Summary
  • Table Of Content
  • Segmentation
  • Request sample

Basal Insulin Market Synopsis:

Basal Insulin Market size was valued at USD 16.4 Billion in 2023, and is Projected to Reach USD 38.36 Billion by 2032, Growing at a CAGR of 9.9% From 2024-2032.

Basal Insulin Market means the market for insulin products used for managing diabetes, especially basal insulin which maintains the blood glucose levels in the body all the day. Basal insulin is given one to two times per day keeping insulin levels constant thus avoiding both hyperglycemia and hypoglyemia. These insulins are important to treat both type 1 and type 2 diabetes and diabetes when the body is unable to produce insulin or make good use of the insulin. Basal insulin can be a short acting insulin or long acting insulin and its delivery method could be syringes, pen or pumps.

The Basal Insulin Market has been growing strongly in the last few years primarily due to the growing incidence of diabetes, a disease which affects a large population worldwide. Due to unhealthy diet and sedentary lifestyle, Type 2 diabetes has increased dramatically across the globe, hence, there and increased need for insulin therapy including the basal insulin. That is why large pharmaceutical companies are paying attention to the creation of newer and more effective preparations, which will serve as the primary factor of market growth. Further, this is also encouraging the changing trends from the conventional methods of treatment for diabetes to a more centralised method, which in effect is driving the demand for basal insulin.

Moreover, people of diabetes type 1 and 2 patients are more aware about the diabetes management and thus the requirement of more long-acting insulin. There is also increased market convenience thanks to improvements in typing of insulin, like pens, pumps, and pre-filled syringes that make insulin delivery to the patient’s body easier and more effective. However, there are several challenges whose prevalence affects the basal insulin market such as; high costs of insulin and problems associated with access to the product in the third world. Such factors prevail to influence the market even with advances in technologies that enhance improving the safety and effectiveness of Insulin products.

Basal Insulin Market Trend Analysis:

Rising prevalence of Diabetes Worldwide

  • The increasing prevalence of diabetes globally, in both developing and developed nations, is a significant driver of the basal insulin market. According to the International Diabetes Federation, over 500 million people are projected to have diabetes by 2030, creating a substantial patient base requiring effective blood glucose management. Basal insulin drugs are crucial for maintaining stable glucose levels, particularly for those with type 1 diabetes and advanced type 2 diabetes. The growing number of diabetes-related hospital admissions presents opportunities for basal insulin adoption within the hospital segment, further fueling market growth and emphasizing the importance of effective treatment solutions.

Digital Health Integration

  • The integration of basal insulin therapies with digital health tools presents a significant market opportunity. Mobile apps, wearable devices, and connected platforms enable real-time glucose monitoring, personalized dosage adjustments, and enhanced telehealth support, improving diabetes management outcomes. These innovations align with the growing demand for patient-centric care, empowering individuals to actively manage their condition. Furthermore, digital tools facilitate data sharing with healthcare providers, enhancing treatment personalization and compliance.

Basal Insulin Market Segment Analysis:

Basal Insulin Market is segmented on the basis of type, delivery device, distribution channel, and region.

By Type, Glargine segment is expected to dominate the market during the forecast period

  • Glargine segment is anticipated to command the basal insulin market throughout the yeast period. Insulin glargine is a long-acting insulin that is now used to treat both type 1 and type 2 diabetes because it produces a steady and consistent glycemic control throughout the day and night. It is a synthetic one relating to the functioning of natural insulin; this is preferable to using regular insulin especially since it is less likely to cause hypoglycemia. Four major insulin glargine brands have already garnered market share and are projected to remain dominant in the course of the forecast period: Sanofi’s Lantus, Boehringer Ingelheim/Eli Lilly’s Basaglar, and others.Also the presence of biosimilar of insulin glargine is improving the market accessibility of this element.

By Delivery Device, Syringes segment is expected to held the largest share

  • The Syringes segment is apt to dominate the basal insulin market because of high acceptance and low cost compared to the other delivery systems. Insulin syringes are the simplest and cheapest basal insulin delivery system, especially in development countries. These are accurate in insulin delivery, user friendly and have the longest time in the market making them the most recommended by patients. Nevertheless, syringes are still the most popular insulin injection devices in terms of the amount used, even with available insulin pens and pumps.Furthermore, the current syringes can be pre-filled and loaded with insulin hence enhancing their ease of use.

Basal Insulin Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • North America is a dominant region in the basal insulin market due to the growing prevalence of diabetes, particularly Type 2 diabetes, which is highly common across the region. The impact of diabetes is notably significant in communities of color, rural areas, and among individuals with lower education levels, limited incomes, and lower health literacy.

These factors contribute to an increased demand for basal insulin, as the management of diabetes becomes essential for improving quality of life. North America's advanced healthcare infrastructure, access to cutting-edge medical technologies, and supportive treatment systems further drive the market's growth. As the diabetic population continues to rise, particularly in underserved communities, the need for basal insulin remains critical, solidifying North America's role as a key player in the global basal insulin market.

Active Key Players in the Basal Insulin Market

  • Amgen Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Boehringer Ingelheim (Germany)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Insulin Human (China)
  • Merck & Co., Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Sanofi (France)
  • Sanofi-Aventis (France)
  • Servier Laboratories (France)
  • Stryker Corporation (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players

Key Industry Development in Basal Insulin Market:

  • In December 2024, Novo Nordisk announced significant reductions in the US list prices of its insulin products, Tresiba and Fiasp, to address the needs of people with diabetes. Effective January 1, 2026, the company lowered the wholesale acquisition costs (WAC) of both vials and pre-filled pens for the rapid-acting insulin aspart (Fiasp) and the long-acting basal insulin (Tresiba) by more than 70%. This move aligns with Novo Nordisk's commitment to improving access to affordable diabetes care in the United States.
  • In March 2023, Eli Lilly and Company announced the launch of its interchangeable insulin glargine biosimilar, Rezvoglar, priced at a 78% discount compared to the originator product, Lantus. This move aligns with Lilly’s commitment to improving access to affordable insulin for patients managing diabetes. The significant price reduction is expected to ease the financial burden for millions of people requiring this essential medication. Rezvoglar, designed to deliver the same efficacy and safety as Lantus, reinforces Lilly’s efforts to provide innovative and accessible solutions in diabetes care.

Basal Insulin Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 16.4 Billion

Forecast Period 2024-32 CAGR:

 9.9%

Market Size in 2032:

USD 38.36 Billion

Segments Covered:

By Type

  • Glargine
  • Detemir
  • Deglude

By Delivery Device

  • Syringes
  • Pens
  • Pumps
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Rising Prevalence of Diabetes Worldwide

Key Market Restraints:

  • High Costs of Insulin

Key Opportunities:

  • Digital Health Integration

Companies Covered in the report:

  • Alfa Laval AB, GEA Group AG, ENCON Evaporators, Dedert Corporation, and Veolia Water Technologies, and Other Active Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Basal Insulin Market by Product
 4.1 Basal Insulin Market Snapshot and Growth Engine
 4.2 Basal Insulin Market Overview
 4.3 Metal bikes Wood bike Other
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Metal bikes Wood bike Other: Geographic Segmentation Analysis

Chapter 5: Basal Insulin Market by Application
 5.1 Basal Insulin Market Snapshot and Growth Engine
 5.2 Basal Insulin Market Overview
 5.3 Commercial Home Use
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Commercial Home Use: Geographic Segmentation Analysis

Chapter 6: Basal Insulin Market by Distribution Channel
 6.1 Basal Insulin Market Snapshot and Growth Engine
 6.2 Basal Insulin Market Overview
 6.3 Online Offline
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Online Offline: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Basal Insulin Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ALLIED CYCLE WORKS (USA)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 BANDIT BIKES (USA)
 7.4 BOBBIN BICYCLES (UK)
 7.5 FROG BIKES (UK)
 7.6 HARO BIKES (USA)
 7.7 ISLABIKES (UK)
 7.8 JOOVY (USA)
 7.9 KAZAM BIKES (USA)
 7.10 MICRO MOBILITY SYSTEMS AG (SWITZERLAND)
 7.11 PUKY GMBH & CO. KG (GERMANY)
 7.12 RADIO FLYER (USA)
 7.13 RIDGEBACK (UK)
 7.14 SPECIALIZED BICYCLE COMPONENTS (USA)
 7.15 STRIDER SPORTS INTERNATIONAL (USA)
 7.16 WOOM BIKES USA (USA)
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Basal Insulin Market By Region
 8.1 Overview
8.2. North America Basal Insulin Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product
  8.2.4.1 Metal bikes Wood bike Other
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Commercial Home Use
  8.2.6 Historic and Forecasted Market Size By Distribution Channel
  8.2.6.1 Online Offline
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
8.3. Eastern Europe Basal Insulin Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product
  8.3.4.1 Metal bikes Wood bike Other
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Commercial Home Use
  8.3.6 Historic and Forecasted Market Size By Distribution Channel
  8.3.6.1 Online Offline
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
8.4. Western Europe Basal Insulin Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product
  8.4.4.1 Metal bikes Wood bike Other
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Commercial Home Use
  8.4.6 Historic and Forecasted Market Size By Distribution Channel
  8.4.6.1 Online Offline
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
8.5. Asia Pacific Basal Insulin Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product
  8.5.4.1 Metal bikes Wood bike Other
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Commercial Home Use
  8.5.6 Historic and Forecasted Market Size By Distribution Channel
  8.5.6.1 Online Offline
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
8.6. Middle East & Africa Basal Insulin Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product
  8.6.4.1 Metal bikes Wood bike Other
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Commercial Home Use
  8.6.6 Historic and Forecasted Market Size By Distribution Channel
  8.6.6.1 Online Offline
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
8.7. South America Basal Insulin Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product
  8.7.4.1 Metal bikes Wood bike Other
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Commercial Home Use
  8.7.6 Historic and Forecasted Market Size By Distribution Channel
  8.7.6.1 Online Offline
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
 

Basal Insulin Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 16.4 Billion

Forecast Period 2024-32 CAGR:

 9.9%

Market Size in 2032:

USD 38.36 Billion

Segments Covered:

By Type

  • Glargine
  • Detemir
  • Deglude

By Delivery Device

  • Syringes
  • Pens
  • Pumps
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Rising Prevalence of Diabetes Worldwide

Key Market Restraints:

  • High Costs of Insulin

Key Opportunities:

  • Digital Health Integration

Companies Covered in the report:

  • Alfa Laval AB, GEA Group AG, ENCON Evaporators, Dedert Corporation, and Veolia Water Technologies, and Other Active Players.
Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Basal Insulin Market research report?

The forecast period in the Basal Insulin Market research report is 2024-2032.

Who are the key players in the Basal Insulin Market?

Alfa Laval AB, GEA Group AG, ENCON Evaporators, Dedert Corporation, Veolia Water Technologies, and Other Active Players.

What are the segments of the Basal Insulin Market?

The Basal Insulin Market is segmented into Type, Delivery Device, Distribution Channel and Region. By Type, the market is categorized into Glargine, Detemir, and Deglude. By Delivery Device, the market is categorized into Syringes, Pens, Pumps, and Others. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Basal Insulin Market?

The Basal Insulin Market means the market for insulin products used for managing diabetes, especially basal insulin which maintains the blood glucose levels in the body all the day. Basal insulin is given one to two times per day keeping insulin levels constant thus avoiding both hyperglycemia and hypoglyemia. These insulins are important to treat both type 1 and type 2 diabetes and diabetes when the body is unable to produce insulin or make good use of the insulin. Basal insulin can be a short acting insulin or long acting insulin and its delivery method could be syringes, pen or pumps.

How big is the Basal Insulin Market?

Basal Insulin Market Size Was Valued at USD 16.4 Billion in 2023, and is Projected to Reach USD 38.36 Billion by 2032, Growing at a CAGR of 9.9% From 2024-2032.